SPRB רווח נקי למניה ב-12 החודשים האחרונים sprucebiosciences.com
Spruce Biosciences (SPRB) enjoys high trust among endocrinologists due to its precise research in the field of adrenal glands. Business growth is driven by tildacerfont trials and high demand within the rare pathology niche. The rolling annual earnings per share clearly demonstrates capital dynamics, where the value -34.79 expresses the state of the metric. The absence of market peers guarantees the company future pricing power and high margins.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_SPRB_-_Spruce-Biosciences_-_Earnings-per-share-for-the-last-four-quarters "Spruce Biosciences - רווח נקי למניה (EPS TTM) SPRB (תקופה 04.07.2022 - 12.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת sprucebiosciences.com (SPRB)
The specifics of clinical protocol outsourcing at Spruce Biosciences (SPRB) make financial results highly sensitive to external contractor costs. The TTM EPS metric digitizes the final net income allocated per common share over one year. This calculation filters out the noise of one-off transactions, revealing the actual inertia of business profitability. Monitoring changes in per-share profit over the last 12 months allows for the timely detection of capital stagnation.
